Comparison of bisacodyl and sodium picosulphate in the treatment of chronic constipation

Kienzle-Horn, Susanne; Vix, Jean-Michel; Schuijt, Chris; Peil, Hubertus; Jordan, Chris; Kamm, Michael A.

doi:10.1185/030079907x178865

Cited by 59 publications

(45 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For bisacodyl, there is a double-blind, randomized, placebo-controlled trial showing efficacy and safety over placebo 114 and another open-labeled, randomized study showing comparable benefits with sodium picosulphate. 113 The level and recommendation for using bisacodyl is superior. Surprisingly, despite the widespread use of senna for more than a century, there is no well-designed RCT comparing its efficacy with placebo.…”

Section: Stimulantsmentioning

confidence: 99%

Chronic Constipation: An Evidence-Based Review

Leung¹,

Riutta²,

Kotecha³

et al. 2011

The Journal of the American Board of Family Medicine

273

168

View full text Add to dashboard Cite

Background: Chronic constipation is a common condition seen in family practice among the elderly and women. There is no consensus regarding its exact definition, and it may be interpreted differently by physicians and patients. Physicians prescribe various treatments, and patients often adopt different over-the-counter remedies. Chronic constipation is either caused by slow colonic transit or pelvic floor dysfunction, and treatment differs accordingly.Methods: To update our knowledge of chronic constipation and its etiology and best-evidence treatment, information was synthesized from articles published in PubMed, EMBASE, and Cochrane Database of Systematic Reviews. Levels of evidence and recommendations were made according to the Strength of Recommendation taxonomy.Results

show abstract

Section: Stimulantsmentioning

confidence: 99%

Chronic Constipation: An Evidence-Based Review

Leung¹,

Riutta²,

Kotecha³

et al. 2011

The Journal of the American Board of Family Medicine

273

168

View full text Add to dashboard Cite

show abstract

“…In a recent 4-week placebo-controlled trial, picosulfate improved bowel function, symptoms, and quality of life [20]. Stimulant laxatives are generally well tolerated, do not cause electrolyte abnormalities, but may induce abdominal pain [1,[3][4][5][6]21]. The latter can often be managed by dose titration [20].…”

Section: Stimulant Laxatives (Phenyl Methanes and Anthraquinones)mentioning

confidence: 97%

Current and future therapies for chronic constipation

Tack

2011

Best Practice & Research Clinical Gastroenterology

View full text Add to dashboard Cite

“…6,8,18 In our study, the tolerability with combination laxatives were considered as good as none of the patients reported any adverse events during the 4-week study period. Present study has several strengths.…”

Section: Discussionmentioning

confidence: 99%

“…In an earlier 4-week study with bisacodyl (5-10 mg daily; n=70) and sodium picosulphate (5-10 mg daily; n=74), in patients with chronic constipation (N=144), a significant improvement in physicians' global assessment was observed in 74.6% patients treated with bisacodyl and 79.2% patients treated with sodium picosulphate. 7,8 However, though these data are existing for individual laxatives, there is no literature available on the combination laxative therapy containing milk of magnesia, liquid paraffin and sodium picosulphate for the management of constipation. Hence the objective of this study was to assess the effectiveness and safety of combination laxative therapy containing milk of magnesia, liquid paraffin and sodium picosulphate in the management of constipation in patients with anal fissure/hemorrhoids/ODS, over the period of 4-weeks.…”

Section: Introductionmentioning

confidence: 99%

A prospective non-comparative study to assess the effectiveness and safety of combination laxative therapy containing milk of magnesia, liquid paraffin and sodium picosulphate (Cremaffin-Plus®) in the management of constipation in patients with anal fissure/hemorrhoids/obstructive defecation syndrome

Patankar

Mishra

2017

Int Surg J

View full text Add to dashboard Cite

Background: Assess the effectiveness and safety of combination laxative therapy containing milk of magnesia, liquid paraffin and sodium picosulphate (Cremaffin-Plus®) in management of constipation, in patients with anal fissure/haemorrhoids/obstructive defecation syndrome (ODS). Methods: Patients visiting study site with complaints of constipation secondary to anal fissures/haemorrhoids/ODS, intended to receive combination laxative therapy (as per physicians' discretion), were enrolled. Primary objectives were to assess the change in number of bowel movements per day and stool consistency; secondary objectives were to assess change in straining, physician global efficacy assessment, quality of life (PAC-QOL score), Constipation Symptoms (CSS), Fecal Incontinence Score (FIS), Patient Assessment of Constipation Symptoms (PAC-SYM) score, along with the Modified Longo Score (MODS) for ODS from baseline to end of 4 weeks. Safety, tolerability and treatment adherence were also assessed. Results: About 32 patients (anal fissure:19, haemorrhoids:5, ODS:8) met inclusion criteria. Significant improvement in stool frequency was observed in all patients pooled together (p=0.016); group wise, statistical significance was noted in patients of anal fissures. Stool consistency was improved in all patients pooled together (p<0.001); group wise, significant improvement was seen in patients of anal fissure and ODS. There was a significant improvement in straining noted in all patients pooled together (p=0.002). Significant reduction (p<0.001) was noted in all the symptom scores (CSS, FIS, PAC-SYM and PAC-QOL) from baseline to 4 weeks in all patients. About 51.44% reduction in MODS score was noted in patients with ODS. Conclusions: Improvement in stool frequency, consistency and straining was noted in all patients with constipation (with fissure/haemorrhoids/ODS) treated with Cremaffin-plus for 4-weeks, improving the quality of life. All patients showed good therapy adherence with better safety and tolerability profile.

show abstract

Comparison of bisacodyl and sodium picosulphate in the treatment of chronic constipation

Abstract: Bisacodyl and sodium picosulphate are equally well tolerated and effective in the treatment of chronic constipation over a 4-week period.

Cited by 59 publications

References 22 publications

Chronic Constipation: An Evidence-Based Review

Chronic Constipation: An Evidence-Based Review

Current and future therapies for chronic constipation

Contact Info

Product

Resources

About